HomeCompareEKTAY vs QYLD

EKTAY vs QYLD: Dividend Comparison 2026

EKTAY yields 2.22% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EKTAY wins by $20.7K in total portfolio value
10 years
EKTAY
EKTAY
● Live price
2.22%
Share price
$5.81
Annual div
$0.13
5Y div CAGR
33.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.1K
Annual income
$7,696.39
Full EKTAY calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — EKTAY vs QYLD

📍 EKTAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEKTAYQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EKTAY + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EKTAY pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EKTAY
Annual income on $10K today (after 15% tax)
$189.12/yr
After 10yr DRIP, annual income (after tax)
$6,541.93/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, EKTAY beats the other by $1,731.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EKTAY + QYLD for your $10,000?

EKTAY: 50%QYLD: 50%
100% QYLD50/50100% EKTAY
Portfolio after 10yr
$35.8K
Annual income
$6,677.86/yr
Blended yield
18.68%
📊

Analyst Conviction Gap

Where Wall Street is split right now

EKTAY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
1.3
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EKTAY buys
0
QYLD buys
0
No recent congressional trades found for EKTAY or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEKTAYQYLD
Forward yield2.22%11.92%
Annual dividend / share$0.13$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.3%0%
Portfolio after 10y$46.1K$25.4K
Annual income after 10y$7,696.39$5,659.31
Total dividends collected$22.9K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: EKTAY vs QYLD ($10,000, DRIP)

YearEKTAY PortfolioEKTAY Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$10,997$296.59$10,352$1,192.36+$645.00EKTAY
2$12,173$406.31$10,830$1,347.57+$1.3KEKTAY
3$13,585$560.31$11,460$1,539.07+$2.1KEKTAY
4$15,315$779.03$12,275$1,777.84+$3.0KEKTAY
5$17,481$1,094.10$13,323$2,078.95+$4.2KEKTAY
6$20,261$1,555.80$14,667$2,463.34+$5.6KEKTAY
7$23,925$2,246.38$16,396$2,960.57+$7.5KEKTAY
8$28,905$3,304.71$18,631$3,612.97+$10.3KEKTAY
9$35,902$4,973.85$21,548$4,482.15+$14.4KEKTAY
10$46,111$7,696.39$25,398$5,659.31+$20.7KEKTAY

EKTAY vs QYLD: Complete Analysis 2026

EKTAYStock

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Full EKTAY Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this EKTAY vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EKTAY vs SCHDEKTAY vs JEPIEKTAY vs OEKTAY vs KOEKTAY vs MAINEKTAY vs XYLDEKTAY vs JEPQEKTAY vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.